{"entity":{"id":"soquelitinib","kind":"drug","name":"Soquelitinib","aka":[],"tldr":"Soquelitinib is an experimental small-molecule drug from Corvus Pharmaceuticals in phase 3 trials for peripheral T-cell lymphomas, with its target not yet stated publicly.","summary":"Soquelitinib (CPI-818) is a small-molecule drug developed by Corvus Pharmaceuticals. The sponsor describes its target as ITK (interleukin-2-inducible T-cell kinase), which OnCo does not yet have a target page for. The sponsor states: An oral, selective ITK inhibitor that promotes Th1 helper cell development while suppressing Th2 and Th17 cells, and can shift differentiation toward regulatory T cells. ClinicalTrials.gov describes the intervention as: Soquelitinib 200 mg tablets will be taken by mouth two times a day. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06561048 (Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma), in peripheral T-cell lymphomas. The largest, NCT06561048, plans to enrol 150 participants with primary completion expected 2027-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Soquelitinib","url":"https://clinicaltrials.gov/search?intr=CPI-818"},{"label":"Sponsor pipeline page","url":"https://corvuspharma.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["corvus-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06561048"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"CPI-818","modality":"small molecule","mechanism":"An oral, selective ITK inhibitor that promotes Th1 helper cell development while suppressing Th2 and Th17 cells, and can shift differentiation toward regulatory T cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/soquelitinib/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"company":[{"id":"corvus-pharmaceuticals","kind":"company","name":"Corvus Pharmaceuticals","route":"/companies/corvus-pharmaceuticals/"}],"trial":[{"id":"nct06561048","kind":"trial","name":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma","route":"/trials/nct06561048/"}],"target":[{"id":"itk","kind":"target","name":"ITK","route":"/targets/itk/"}]}}